(Report ID: 180035) Drug interactions analysis of: Midazolam Hydrochloride, Vecuronium Bromide, Dopamine Hcl, Verapamil HydrochlorideMany drug interactions and side effects can not be detected until the drugs have been used by millions of people, and for a long time. Large, long-term drug safety studies are ideal to discover these real-world drug outcomes. For the first time, eHealthMe enables health professionals and patients to conduct these studies for their drugs. Click here to check your drugs now, in a whole new way. As of Nov, 20, 2008, eHealthMe analyzes 10,180,591 drug interactions and side effects of 21,667 FDA-approved drugs from 1977 to the present. Results on Nov, 20, 2008: 9 relevant incidents
Note:
- The incidents can not include all actual occurrences
- Data of 2008 is not complete
DISCLAIMER: All adverse drug reaction material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. Basic information:
| Report ID | Date of submission | Patient age | Patient gender |
| 180035 | Aug, 3, 2006 | 70 | Male |
List of drugs the patient takes:
| Drug |
Midazolam Hydrochloride |
Vecuronium Bromide |
Dopamine Hcl |
Verapamil Hydrochloride |
List of drug interactions, adverse side effects / events the patient has:
| Name |
Condition Aggravated |
Disease Progression |
Haemorrhagic Diathesis |
Hepatic Ischaemia |
Liver Disorder |
Results from eHealthMe: 9 relevent incidents1) Comparison with the patient's adverse outcomes:
| Name | Count (% of total reports) |
Condition Aggravated | 2 (22.22%) |
Disease Progression | 1 (11.11%) |
Haemorrhagic Diathesis | 3 (33.33%) |
Hepatic Ischaemia | 2 (22.22%) |
Liver Disorder | 2 (22.22%) |
2) Top drug interactions, adverse side effects reported for the past 12 months:
3) Top co-used drugs drugs reported for the past 12 months:
4) Top drug interactions, adverse side effects reported of all time:Death: 0 Cancer: 0
| Name | Count (% of total reports) |
1 | Multi-organ Failure | 3 (33.33%) |
2 | Haemorrhagic Diathesis | 3 (33.33%) |
3 | Liver Function Tests Nos Abnormal | 3 (33.33%) |
4 | Condition Aggravated | 2 (22.22%) |
5 | Hepatic Failure | 2 (22.22%) |
6 | Adult Respiratory Distress Syndrome | 2 (22.22%) |
7 | Mediastinitis | 2 (22.22%) |
8 | Liver Disorder | 2 (22.22%) |
9 | Hepatic Ischaemia | 2 (22.22%) |
10 | Hepatic Disorder Nos | 1 (11.11%) |
5) Top co-used drugs drugs reported of all time:
| Name | Count |
1 | Potassium Chloride | 6 |
2 | Digoxin | 5 |
3 | Propulsid | 3 |
4 | Penicillin | 3 |
5 | Midazolam Hcl | 3 |
6 | Sucralfate | 3 |
7 | Morphine | 3 |
8 | Atrovent | 3 |
9 | Ventolin | 3 |
10 | Isoptin | 3 |
Want to have a risk analysis report like this for your drugs? Click here. ADVERTISEMENT
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Recent drug risk analysis reports:
Adderall Xr 25 (Shire) - 6.25MG;6.25M... for Add (Nov, 20, 2008)
|
Suboxone (Reckitt Benckiser) - 8MG;2MG for Opitate Addiction (Nov, 20, 2008)
|
Strattera (Lilly) - 60MG for ADHD (Nov, 20, 2008)
|
Strattera (Lilly) - 60MG for ADHD (Nov, 20, 2008)
|
Side effects comparison of Depakote Er (Abbott) - 500MG (Nov, 20, 2008)
|
Coreg (Smithkline Beecham) - 6.25MG for Tachycardia (Nov, 20, 2008)
|
Tramadol Hydrochloride And Acetaminop... for Pain - Bones (Nov, 20, 2008)
|
Side effects comparison of Azithromycin (Abraxis Pharm) - EQ 500... (Nov, 20, 2008)
|
Digoxin (0.25mg) Lannett for Heart Disease (Nov, 20, 2008)
|
Side effects comparison of Abilify (Otsuka) (Nov, 20, 2008)
|
|
|
|
 |
|
How to use the report?
Bring a copy of this report to a doctor's appointment to ensure drug risks are fully discussed and understood, in the process of risk and benefit assessment.
|
 |
|
ADVERTISEMENT
|
|